This histogram enumerates side effects from a completed 2021 Phase 2 trial (NCT04435184) in the Crizanlizumab ARM group. Side effects include: Chest pain with 8%, Dark and Infrequent Urination with 4%, Venous thrombembolism with 4%, Diarrhea with 4%, Altered mental status with 4%.
1 Treatment Group
1 of 1
130 Total Participants · 1 Treatment Group
Primary Treatment: Crizanlizumab · No Placebo Group · Phase 4
Experimental Group · 1 Intervention: Crizanlizumab · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: from day of first dose of study medication to 105 days after last dose of study medication
Who is running the clinical trial?
Novartis PharmaceuticalsLead Sponsor
2,692 Previous Clinical Trials
3,522,909 Total Patients Enrolled
18 Trials studying Anemia, Sickle Cell
4,181 Patients Enrolled for Anemia, Sickle Cell
Age Any Age · All Participants · 3 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
According to local guidelines, written informed consent/assent must be signed by adult patients
The patient is currently enrolled in a Novartis-sponsored study receiving crizanlizumab and has fulfilled all the requirements in the parent study
The patient has complied with the planned visit schedule in the parent study, and the investigator believes that the patient is willing and able to comply with future visit schedules.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.